GLP-1 medicines and thiamine deficiency risk

The case record

The first widely cited report (Sheth et al., Cureus 2024) described non-alcoholic Wernicke encephalopathy temporally associated with semaglutide in a 37-year-old man, with characteristic MRI abnormalities of the basal ganglia, thalami and brainstem. A BMC Neurology case added severe axonal polyneuropathy alongside encephalopathy after rapid weight loss on semaglutide. Most gravely, a Cureus longitudinal PET case report documented irreversible Korsakoff syndrome after rapid weight loss on tirzepatide, with persistent deficits despite intravenous thiamine — the authors explicitly urge nutritional assessment and consideration of thiamine supplementation when initiating these therapies.

Bidesie and Oudman’s PRISMA systematic review (Obesity 2026) gathered six Wernicke encephalopathy cases after semaglutide for obesity. Every case involved prolonged gastrointestinal symptoms and substantial weight loss before neurological deterioration; outcomes included Korsakoff progression and death. The reviewers’ clinical message: vigilance for thiamine deficiency whenever gastrointestinal intolerance persists or weight falls rapidly, and early parenteral thiamine when deficiency is suspected.

The pharmacovigilance signals

Lev and colleagues analysed FAERS and found disproportionate reporting of Wernicke encephalopathy with GLP-1 receptor agonists — 15 cases, mostly semaglutide and tirzepatide, ROR 2.35 (95% CI 1.38–4.01); 13 of 15 involved weight loss, vomiting, appetite loss or malnutrition, and 7 of 11 with follow-up had long-term sequelae. Gras and colleagues found 19 cases in WHO VigiBase: 68% with nausea/vomiting or reduced intake, weight loss of 3.5–13.3 kg per month over 3–6 months, and disproportionate reporting for semaglutide, tirzepatide and the class as a whole.

These are signals, not incidence rates. Spontaneous-report disproportionality cannot prove causality, carries reporting bias, and gives no denominator. What it does is tell the field where to look — and it is looking at thiamine.

The consensus response

Professional bodies on both sides of the Atlantic have now formalised the concern. A joint advisory of the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society (AJCN 2025) identifies nutritional deficiencies from calorie reduction as a key GLP-1 challenge and advises baseline dietary screening and GI side-effect management. A European EASO/EFAD/ECPO consensus statement (Lancet Diabetes & Endocrinology 2026) proposes pragmatic monitoring of diet quality and micronutrient risk during incretin therapy and calls for longitudinal research on micronutrient status. Neither document provides a thiamine-specific protocol — the guidance layer is ahead of the trial layer.

Where retatrutide fits

Retatrutide combines GLP-1 with GIP and glucagon agonism and produces larger average weight reductions than earlier agents, with gastrointestinal events the most frequent adverse events in its trials. No Wernicke case has been attributed to retatrutide in the verified literature — and no thiamine-status study in retatrutide-treated individuals exists either. Reta-B1 treats that combination as an argument for engineered nutritional architecture and measurement, not for alarm or for complacency.